Valuation: AstraZeneca PLC

Market Cap 256B 219B 205B 188B 352B 24,476B 359B 2,425B 945B 12,288B 960B 939B 40,643B P/E 2026 *
21.1x
P/E 2027 * 18.4x
Enterprise Value 275B 235B 220B 202B 379B 26,326B 387B 2,608B 1,016B 13,216B 1,033B 1,010B 43,713B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 4x
Free-Float
96.63%
Yield 2026 *
2.02%
Yield 2027 * 2.14%
1 day-1.23%
1 week+2.64%
Current month-5.02%
1 month-6.48%
3 months-12.52%
6 months-19.28%
Current year-11.53%
1 week 134
Extreme 134
141.8
1 month 134
Extreme 134
154
Current year 134
Extreme 134
180.45
1 year 125
Extreme 125
180.45
3 years 112.45
Extreme 112.45
180.45
5 years 94.11
Extreme 94.11
180.45
10 years 47.74
Extreme 47.74
180.45
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%+2.64% - - 254B
-2.81%+1.98%+76.96%+127.73% 1,141B
-2.21%+2.50%+50.38%+55.01% 659B
-1.56%+5.25%+26.98%+74.39% 470B
+1.20%+1.72%+42.89%+45.78% 366B
-0.61%+1.72%+25.21%+41.34% 302B
+0.32%+3.30%+2.60%+13.42% 254B
-1.95%+4.22%+46.75%+65.66% 239B
-1.10%-1.12%-14.91%-52.66% 207B
-2.82%+5.57%+21.58%+89.04% 183B
Average -1.28%+4.10%+30.94%+51.08% 424.55B
Weighted average by Cap. -1.62%+4.31%+44.42%+70.86%

Financials

2026 *2027 *
Net sales 63.25B 54.12B 50.58B 46.37B 87.15B 6,052B 88.87B 600B 234B 3,039B 237B 232B 10,050B 66.84B 57.2B 53.45B 49B 92.1B 6,396B 93.91B 634B 247B 3,211B 251B 245B 10,621B
Net income 12.07B 10.33B 9.65B 8.85B 16.63B 1,155B 16.96B 114B 44.58B 580B 45.32B 44.33B 1,918B 13.72B 11.74B 10.97B 10.06B 18.9B 1,313B 19.27B 130B 50.66B 659B 51.5B 50.37B 2,179B
Net Debt 19.33B 16.54B 15.46B 14.17B 26.63B 1,849B 27.15B 183B 71.39B 928B 72.56B 70.98B 3,071B 11.65B 9.97B 9.32B 8.54B 16.06B 1,115B 16.37B 110B 43.04B 560B 43.75B 42.79B 1,852B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-08-20 €140.05 -1.23% 337
26-08-19 €141.80 +3.09% 1,293
26-08-18 €137.55 +1.14% 670
26-08-17 €136.00 +1.00% 1,598
26-08-14 €134.65 -2.21% 4,134
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
164.91USD
Average target price
212.30USD
Spread / Average Target
+28.74%

Quarterly revenue - Rate of surprise